Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

17.39 -0.46 (-2.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 238,844
Open 17.60
Bid (Size) 7.060 (2)
Ask (Size) 21.42 (10)
Prev. Close 17.85
Today's Range 16.91 - 18.30
52wk Range 13.37 - 32.27
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
From Dianthus Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-25.0%
-25.0%
1 Month
-18.9%
-18.9%
3 Month
-19.5%
-19.5%
6 Month
-25.8%
-25.8%
1 Year
-20.7%
-20.7%

More News

Read More
Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views
Via Benzinga
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics
Via Benzinga
Evaluating Dianthus Therapeutics: Insights From 5 Financial Analysts
Via Benzinga
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate in Two Upcoming Investor Events
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Friday's pre-market session: top gainers and losers
Via Chartmill
A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts
Via Benzinga
Expert Ratings For Dianthus Therapeutics
Via Benzinga
Navigating 4 Analyst Ratings For Dianthus Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Ulta Beauty Reports Downbeat Results, Joins Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace

Frequently Asked Questions

Is Dianthus Therapeutics, Inc. - Common Stock publicly traded?
Yes, Dianthus Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Dianthus Therapeutics, Inc. - Common Stock trade on?
Dianthus Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Dianthus Therapeutics, Inc. - Common Stock?
The ticker symbol for Dianthus Therapeutics, Inc. - Common Stock is DNTH on the Nasdaq Stock Market
What is the current price of Dianthus Therapeutics, Inc. - Common Stock?
The current price of Dianthus Therapeutics, Inc. - Common Stock is 17.39
When was Dianthus Therapeutics, Inc. - Common Stock last traded?
The last trade of Dianthus Therapeutics, Inc. - Common Stock was at 05/30/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback